Handel vTv Therapeutics Inc. - VTVT CFD
Føj til favorit- Opsummering
- Historisk Data
- Begivenheder
- Resultatopgørelse
- Saldo
- Cash flow
- Ejerskab
Spænd | 0.06 | ||||||||
Long position, gebyr natten over
Long position overnight fee
Gå til platform | -0.024068% | ||||||||
Short position, gebyr natten over
Short position overnight fee
Gå til platform | 0.001846% | ||||||||
Gebyr natten over, tid | 21:00 (UTC) | ||||||||
Min. handlet mængde | 1 | ||||||||
Valuta | USD | ||||||||
Margen | 20% | ||||||||
Aktiebørs | United States of America | ||||||||
Kommission på handel | 0% |
*Information provided by Capital.com
Tidligere luk* | 0.76 |
Åben* | 0.74 |
1-Års Ændring* | 19.35% |
Dagens Spænd* | 0.73 - 0.76 |
52-Ugers Spænd | 0.38-1.40 |
Gennemsnitlig Volumen (10 dage) | 66.30K |
Gennemsnitlig Volumen (3 måneder) | 2.25M |
Market Cap | 81.05M |
P/E-forhold | -100.00K |
Udestående aktier | 104.58M |
Omsætning | 2.02M |
EPS | -0.26 |
Dividend (Udbytte %) | N/A |
Beta | -1.17 |
Næste indtjeningsopgørelse | May 10, 2023 |
Al data kommer fra Refinitiv, med undtagelse af data markeret med en asterisk, som er *data fra Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Luk | Change | Change (%) | Åben | High | Low |
---|---|---|---|---|---|---|
Mar 22, 2023 | 0.73 | -0.01 | -1.35% | 0.74 | 0.76 | 0.73 |
Mar 21, 2023 | 0.76 | 0.02 | 2.70% | 0.74 | 0.76 | 0.74 |
Mar 20, 2023 | 0.74 | 0.01 | 1.37% | 0.73 | 0.75 | 0.73 |
Mar 17, 2023 | 0.74 | 0.00 | 0.00% | 0.74 | 0.75 | 0.72 |
Mar 16, 2023 | 0.77 | 0.01 | 1.32% | 0.76 | 0.77 | 0.75 |
Mar 15, 2023 | 0.77 | 0.00 | 0.00% | 0.77 | 0.79 | 0.77 |
Mar 14, 2023 | 0.77 | 0.03 | 4.05% | 0.74 | 0.77 | 0.74 |
Mar 13, 2023 | 0.74 | 0.04 | 5.71% | 0.70 | 0.76 | 0.68 |
Mar 10, 2023 | 0.69 | -0.08 | -10.39% | 0.77 | 0.77 | 0.67 |
Mar 9, 2023 | 0.78 | -0.04 | -4.88% | 0.82 | 0.82 | 0.77 |
Mar 8, 2023 | 0.82 | -0.08 | -8.89% | 0.90 | 0.90 | 0.81 |
Mar 7, 2023 | 0.86 | -0.01 | -1.15% | 0.87 | 0.92 | 0.85 |
Mar 6, 2023 | 0.91 | 0.02 | 2.25% | 0.89 | 0.92 | 0.79 |
Mar 3, 2023 | 0.76 | -0.01 | -1.30% | 0.77 | 0.77 | 0.75 |
Mar 2, 2023 | 0.77 | -0.04 | -4.94% | 0.81 | 0.81 | 0.76 |
Mar 1, 2023 | 0.79 | 0.00 | 0.00% | 0.79 | 0.80 | 0.78 |
Feb 28, 2023 | 0.79 | 0.04 | 5.33% | 0.75 | 0.79 | 0.75 |
Feb 27, 2023 | 0.75 | -0.04 | -5.06% | 0.79 | 0.80 | 0.75 |
Feb 24, 2023 | 0.78 | -0.01 | -1.27% | 0.79 | 0.79 | 0.78 |
Feb 23, 2023 | 0.82 | -0.01 | -1.20% | 0.83 | 0.83 | 0.81 |
vTv Therapeutics Inc. Events
Tid (UTC) (UTC) | Land | Begivenhed |
---|---|---|
No events scheduled |
- Årlig
- Pr kvartal
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Total omsætning | 4.005 | 6.414 | 2.764 | 12.434 | 0.291 |
Omsætning | 4.005 | 6.414 | 2.764 | 12.434 | 0.291 |
Totale Driftsudgifter | 25.667 | 18.266 | 23.656 | 32.258 | 50.973 |
Salgs/Generelle/Admin. Udgifter, Total | 11.443 | 7.251 | 8.537 | 9.223 | 11.333 |
Forskning & Udvikling | 12.624 | 11.015 | 15.119 | 23.035 | 39.64 |
Driftsindtægter | -21.662 | -11.852 | -20.892 | -19.824 | -50.682 |
Renteindkomst (Udgift), Netto Ikke-Drift | -0.011 | -0.68 | -1.774 | -3.229 | -2.975 |
Andre, Netto | 4.057 | -0.27 | 0.828 | -0.592 | -0.19 |
Netto Indkomst Før Skat | -17.616 | -12.802 | -21.838 | -23.645 | -53.847 |
Netto Indkomst Efter Skat | -17.731 | -12.802 | -21.938 | -23.845 | -48.8 |
Minoritetsrente | 4.744 | 4.303 | 8.894 | 15.934 | 38.503 |
Netto Indkomst Før Ekstra Ting | -12.987 | -8.499 | -13.044 | -7.911 | -10.297 |
Netto Indkomst | -12.987 | -8.499 | -13.044 | -7.911 | -16.144 |
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -12.987 | -8.499 | -17.913 | -8.65 | -10.297 |
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -12.987 | -8.499 | -17.913 | -8.65 | -16.144 |
Fortyndet Netto Indkomst | -12.987 | -8.499 | -17.913 | -8.65 | -16.144 |
Fortyndet Vægtet Gennemsnit Aktier | 60.7326 | 47.1379 | 30.292 | 12.4492 | 9.69325 |
Fortyndet EPS Uden Ekstraordinære Ting | -0.21384 | -0.1803 | -0.59134 | -0.69482 | -1.06229 |
Dividends per Share - Common Stock Primary Issue | 0 | ||||
Fortyndet Normaliseret EPS | -0.19671 | -0.1803 | -0.59134 | -0.69482 | -1.06229 |
Totale Ekstraordinære Ting | -5.847 | ||||
Total Adjustments to Net Income | 0 | -4.869 | -0.739 | ||
Usædvanlig Udgift (Indkomst) | 1.6 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Total omsætning | 2 | 0.009 | 3 | 0.009 | 0.987 |
Omsætning | 2 | 0.009 | 3 | 0.009 | 0.987 |
Totale Driftsudgifter | 8.481 | 11.118 | 4.603 | 4.679 | 5.267 |
Salgs/Generelle/Admin. Udgifter, Total | 5.348 | 5.716 | 2.221 | 2.242 | 2.164 |
Forskning & Udvikling | 3.133 | 5.402 | 2.382 | 2.437 | 3.103 |
Driftsindtægter | -6.481 | -11.109 | -1.603 | -4.67 | -4.28 |
Renteindkomst (Udgift), Netto Ikke-Drift | -0.001 | -0.006 | -0.006 | 0 | 0.001 |
Andre, Netto | -2.742 | 1.632 | 0.244 | 3.829 | -1.648 |
Netto Indkomst Før Skat | -9.224 | -9.483 | -1.365 | -0.841 | -5.927 |
Netto Indkomst Efter Skat | -9.424 | -9.483 | -1.465 | -0.841 | -5.942 |
Minoritetsrente | 2.417 | 2.432 | 0.378 | 0.233 | 1.701 |
Netto Indkomst Før Ekstra Ting | -7.007 | -7.051 | -1.087 | -0.608 | -4.241 |
Netto Indkomst | -7.007 | -7.051 | -1.087 | -0.608 | -4.241 |
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -7.007 | -7.051 | -1.087 | -0.608 | -4.241 |
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -7.007 | -7.051 | -1.087 | -0.608 | -4.241 |
Fortyndet Netto Indkomst | -7.007 | -7.051 | -1.087 | -0.608 | -4.241 |
Fortyndet Vægtet Gennemsnit Aktier | 66.9428 | 66.719 | 61.0733 | 58.6151 | 56.4725 |
Fortyndet EPS Uden Ekstraordinære Ting | -0.10467 | -0.10568 | -0.0178 | -0.01037 | -0.0751 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Fortyndet Normaliseret EPS | -0.10467 | -0.10568 | -0.0178 | -0.01037 | -0.0751 |
- Årlig
- Pr kvartal
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Totale Nuværende Aktiver | 15.621 | 7.215 | 2.838 | 3.473 | 20.362 |
Likvider og Kortsigtede Investeringer | 13.415 | 5.747 | 1.777 | 1.683 | 11.758 |
Likvider & Lignende | 13.415 | 5.747 | 1.777 | 1.683 | 11.758 |
Totale Tilgodehavender, Netto | 0.057 | 0.158 | 0.005 | 0 | 8 |
Accounts Receivable - Trade, Net | 0.057 | 0.158 | 0.005 | 0 | 8 |
Prepaid Expenses | 1.914 | 0.939 | 0.806 | 0.666 | 0.442 |
Total Assets | 25.474 | 14.789 | 9.266 | 8.559 | 27.917 |
Property/Plant/Equipment, Total - Net | 0.68 | 0.849 | 1.004 | 0.07 | 0.283 |
Property/Plant/Equipment, Total - Gross | 0.985 | 1.065 | 1.152 | 8.501 | 9.399 |
Accumulated Depreciation, Total | -0.305 | -0.216 | -0.148 | -8.431 | -9.116 |
Other Long Term Assets, Total | 0 | 2.944 | 2.536 | 4.792 | |
Total Current Liabilities | 8.498 | 6.39 | 13.381 | 18.837 | 26.929 |
Accounts Payable | 1.876 | 1.925 | 2.232 | 2.899 | 2.269 |
Payable/Accrued | |||||
Accrued Expenses | 6.331 | 4.35 | 4.946 | 4.803 | 11.632 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 0.035 | 0.031 | 0.031 | 1.752 | 8.757 |
Total Liabilities | 35.214 | 94.891 | 58.289 | 91.412 | 178.964 |
Total Long Term Debt | 0 | 0 | 0 | 6.33 | 15.316 |
Long Term Debt | 0 | 6.33 | 15.316 | ||
Minority Interest | 24.962 | 83.895 | 40.183 | 62.482 | 131.44 |
Other Liabilities, Total | 1.754 | 4.606 | 4.725 | 3.763 | 5.279 |
Total Equity | -9.74 | -80.102 | -49.023 | -82.853 | -151.047 |
Common Stock | 0.901 | 0.773 | 0.641 | 0.435 | 0.329 |
Additional Paid-In Capital | 238.193 | 209.161 | 183.858 | 150.595 | 127.682 |
Retained Earnings (Accumulated Deficit) | -248.834 | -290.036 | -233.522 | -233.883 | -279.058 |
Total Liabilities & Shareholders’ Equity | 25.474 | 14.789 | 9.266 | 8.559 | 27.917 |
Total Common Shares Outstanding | 90.0366 | 77.1449 | 64.0127 | 43.4413 | 32.8125 |
Other Current Assets, Total | 0.235 | 0.371 | 0.25 | 1.124 | 0.162 |
Long Term Investments | 9.173 | 6.725 | 2.48 | 2.48 | 2.48 |
Current Port. of LT Debt/Capital Leases | 0.256 | 0.084 | 6.172 | 9.383 | 4.271 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Totale Nuværende Aktiver | 13.612 | 15.621 | 22.171 | 11.272 | 9.221 |
Likvider og Kortsigtede Investeringer | 12.138 | 13.415 | 19.566 | 10.835 | 8.449 |
Likvider & Lignende | 12.138 | 13.415 | 19.566 | 10.835 | 8.449 |
Totale Tilgodehavender, Netto | 0.057 | 0.057 | 0.928 | 0 | 0.002 |
Accounts Receivable - Trade, Net | 0.057 | 0.057 | 0.928 | 0 | 0.002 |
Prepaid Expenses | 1.387 | 2.049 | 1.574 | 0.313 | 0.71 |
Other Current Assets, Total | 0.03 | 0.1 | 0.103 | 0.124 | 0.06 |
Total Assets | 20.185 | 25.474 | 31.434 | 21.66 | 16.754 |
Property/Plant/Equipment, Total - Net | 0.634 | 0.68 | 0.724 | 0.766 | 0.808 |
Long Term Investments | 5.939 | 9.173 | 8.539 | 9.622 | 6.725 |
Total Current Liabilities | 12.7 | 8.498 | 5.51 | 5.059 | 5.162 |
Payable/Accrued | 12.474 | 8.023 | 4.663 | 4.855 | 4.965 |
Accrued Expenses | 0.191 | 0.184 | 0.176 | 0.169 | 0.162 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0 | 0.256 | 0.636 | 0 | 0 |
Other Current Liabilities, Total | 0.035 | 0.035 | 0.035 | 0.035 | 0.035 |
Total Liabilities | 28.278 | 35.214 | 52.979 | 69.483 | 73.029 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 14.367 | 24.962 | 44.61 | 60.19 | 62.647 |
Other Liabilities, Total | 1.211 | 1.754 | 2.859 | 4.234 | 5.22 |
Total Equity | -8.093 | -9.74 | -21.545 | -47.823 | -56.275 |
Common Stock | 0.901 | 0.901 | 0.897 | 0.834 | 0.808 |
Additional Paid-In Capital | 238.669 | 238.193 | 236.557 | 224.457 | 217.647 |
Retained Earnings (Accumulated Deficit) | -247.663 | -248.834 | -258.999 | -273.114 | -274.73 |
Total Liabilities & Shareholders’ Equity | 20.185 | 25.474 | 31.434 | 21.66 | 16.754 |
Total Common Shares Outstanding | 90.0366 | 90.0366 | 89.565 | 83.2878 | 80.6658 |
- Årlig
- Pr kvartal
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Netto indkomst/Startlinje | -17.731 | -12.802 | -21.938 | -23.845 | -54.647 |
Likvider Fra Driftsaktiviteter | -19.308 | -18 | -23.018 | -26.856 | -44.56 |
Likvider Fra Driftsaktiviteter | 0.089 | 0.094 | 0.039 | 0.218 | 0.197 |
Ikke-Likvide Ting | -1.701 | -2.586 | 0.935 | 4.316 | 4.853 |
Likvid Rente Betalt | 0.011 | 0.623 | 1.295 | 2.276 | 2.064 |
Ændringer i Driftskapital | 0.035 | -2.706 | -2.054 | -7.545 | 5.037 |
Likvider fra Investeringsaktiviteter | 0 | 0 | 0.242 | 0.007 | -0.025 |
Kapitaludgifter | 0 | 0 | -0.07 | -0.005 | -0.057 |
Andre Investerings-Cash-Flow-Ting, Total | 0 | 0 | 0.312 | 0.012 | 0.032 |
Likvider fra Financieringsaktiviteter | 26.976 | 19.47 | 22.87 | 16.612 | 7.5 |
Financiering af Cash-Flow-Ting | 0 | 0 | |||
Udstedelse (Pensionering) af Aktier, Netto | 26.804 | 24.426 | 32.943 | 21.5 | 0 |
Udstedelse (Pensionering) af Gæld, Netto | 0.172 | -4.956 | -10.073 | -4.888 | 7.5 |
Netto Ændring i Likviditet | 7.668 | 1.47 | 0.094 | -10.237 | -37.085 |
Cash Taxes Paid | 0.115 | 0 | 0.1 | 1 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Net income/Starting Line | -9.424 | -17.731 | -8.248 | -6.783 | -5.942 |
Cash From Operating Activities | -1.021 | -19.308 | -12.891 | -9.297 | -5.299 |
Cash From Operating Activities | 0.023 | 0.089 | 0.067 | 0.045 | 0.023 |
Non-Cash Items | 3.218 | -1.701 | -1.063 | -1.292 | 2.084 |
Changes in Working Capital | 5.162 | 0.035 | -3.647 | -1.267 | -1.464 |
Cash From Financing Activities | -0.256 | 26.976 | 26.71 | 14.385 | 8.001 |
Issuance (Retirement) of Stock, Net | 0 | 26.804 | 26.158 | 14.469 | 8.085 |
Issuance (Retirement) of Debt, Net | -0.256 | 0.172 | 0.552 | -0.084 | -0.084 |
Net Change in Cash | -1.277 | 7.668 | 13.819 | 5.088 | 2.702 |
Cash From Investing Activities | 0 | ||||
Capital Expenditures | 0 | ||||
Other Investing Cash Flow Items, Total | 0 |
Investornavn | Investortype | Procent udestående | Aktiebeholdning | Aktieændring | Beholdningsdato | IOmsætningsscore |
---|---|---|---|---|---|---|
MacAndrews & Forbes Holdings, Inc. | Holding Company | 44.9246 | 36606212 | 87000 | 2022-05-31 | LOW |
G42 Investments AI Holdings RSC, Ltd. | Corporation | 12.7465 | 10386274 | 10386274 | 2022-05-31 | LOW |
Medpace Investors, L.L.C. | Corporation | 6.6241 | 5397529 | 5397529 | 2022-08-16 | LOW |
Samsara BioCapital, LLC | Venture Capital | 2.0072 | 1635509 | 0 | 2022-12-31 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 1.1531 | 939623 | 653 | 2022-12-31 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.3551 | 289347 | -653 | 2022-12-31 | LOW |
Veritable, L.P. | Investment Advisor/Hedge Fund | 0.2981 | 242937 | 222032 | 2022-12-31 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.1654 | 134745 | 0 | 2022-12-31 | LOW |
Millennium Management LLC | Hedge Fund | 0.0786 | 64078 | -13261 | 2022-12-31 | HIGH |
Fry (John Anthony) | Individual Investor | 0.0749 | 61000 | 61000 | 2022-11-29 | LOW |
Nelson (Rich S) | Individual Investor | 0.0736 | 60000 | 0 | 2022-04-04 | |
HBKS Wealth Advisors | Investment Advisor | 0.0708 | 57694 | 57694 | 2022-12-31 | MED |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.0659 | 53660 | -185 | 2022-12-31 | LOW |
Citadel Advisors LLC | Hedge Fund | 0.06 | 48860 | 15848 | 2022-12-31 | HIGH |
Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.0498 | 40577 | 0 | 2022-12-31 | LOW |
Two Sigma Investments, LP | Hedge Fund | 0.0467 | 38052 | 5667 | 2022-12-31 | HIGH |
Morgan Stanley Smith Barney LLC | Investment Advisor | 0.041 | 33442 | 0 | 2022-12-31 | LOW |
Simon Quick Advisors, LLC | Investment Advisor | 0.0368 | 30000 | 0 | 2022-12-31 | MED |
Bridgeway Capital Management, LLC | Investment Advisor | 0.0332 | 27018 | 0 | 2022-12-31 | LOW |
Kozlov (Hersh) | Individual Investor | 0.0307 | 25000 | 0 | 2022-04-04 |
Hvorfor vælge Capital.com? Vores tal taler for sig selv.
Capital.com Group500K+
Handlende
92K+
Månedlkige, aktive klienter
$53M+
Månedlig investeringsvolumen
$30M+
Hævet hver måned
Handelslommeregner
Udregn dit hypotetiske P&L hvis du havde åbnet en CFD-handel på en given dato (vælg en dato) og lukket den på en anden dato (vælg en dato).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
vTv Therapeutics Inc. Company profile
Om vTv Therapeutics Inc.
vTv Therapeutics Inc. er en farmaceutisk virksomhed i klinisk fase, som beskæftiger sig med opdagelse og udvikling af oralt administrerede små molekylære lægemiddelkandidater. Virksomheden er ved at udvikle et program til behandling af type I-diabetes TTP399 og til behandling af psoriasis HPP737. TTP399 er en oralt administreret, lille molekylær, leverselektiv glukokinaseaktivator (GKA), der er under udvikling som et potentielt oralt antidiabetikum til behandling af type I-diabetes. TTP399 afsluttede SimpliciT-I-undersøgelsen, et fase II-forsøg i patienter med type I-diabetes som supplement til insulinbehandling. Selskabet gennemfører også en fase I-undersøgelse med flere stigende doser af HPP737, en oralt administreret fosfodiesterase type IV-hæmmer, for at vurdere HPP737's farmakokinetik, farmakodynamik, sikkerhed og tolerabilitet hos raske frivillige som en del af dets psoriasisprogram. TTP273 er en oral, småmolekylær glukagonlignende peptid I (GLP-1)-receptoragonist, der evalueres til behandling af type II-diabetes mellitus.
Industry: | Bio Therapeutic Drugs |
3980 Premier Dr
Suite 310
HIGH POINT
NORTH CAROLINA 27265
US
Resultatopgørelse
- Annual
- Quarterly
Folk ser også
Leder du stadig efter en mægler, du kan stole på?
Deltag sammen med 500.000+ handlende over hele verden, der valgte at handle hos Capital.com